Merck's efinopegdutide meets primary endpoint in Phase 2b MASH trial

• Merck reported positive Phase 2b results for investigational efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis.
• The once-weekly injectable met its primary endpoint, improving MASH resolution without worsening liver scarring compared with placebo.
• Treatment also improved liver scarring without worsening steatohepatitis.
• Safety was generally consistent with semaglutide; treatment discontinuations due to adverse events were higher with efinopegdutide.
• Results were presented at The Liver Meeting in Denver and simultaneously published in The Lancet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109820711) on November 09, 2026, and is solely responsible for the information contained therein.